[go: up one dir, main page]

WO2010088000A3 - Composés antifibrotiques et leurs utilisations - Google Patents

Composés antifibrotiques et leurs utilisations Download PDF

Info

Publication number
WO2010088000A3
WO2010088000A3 PCT/US2010/000287 US2010000287W WO2010088000A3 WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3 US 2010000287 W US2010000287 W US 2010000287W WO 2010088000 A3 WO2010088000 A3 WO 2010088000A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
antifibrotic compounds
antifibrotic
subclasses
classes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/000287
Other languages
English (en)
Other versions
WO2010088000A2 (fr
Inventor
Itzhak D. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of WO2010088000A2 publication Critical patent/WO2010088000A2/fr
Publication of WO2010088000A3 publication Critical patent/WO2010088000A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés ayant les formules (I), (II) et (III) : F et leurs dérivés pharmaceutiquement acceptables, comme il est décrit généralement et par classes et sous-classes ici, et elle concerne en outre des compositions pharmaceutiques les contenant, et des procédés pour les utiliser pour le traitement de l'un quelconque de nombreux états et maladies impliquant une fibrose et pour lesquels une activité antifibrotique est bénéfique.
PCT/US2010/000287 2009-02-02 2010-02-02 Composés antifibrotiques et leurs utilisations Ceased WO2010088000A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20661509P 2009-02-02 2009-02-02
US61/206,615 2009-02-02
US21474409P 2009-04-28 2009-04-28
US61/214,744 2009-04-28

Publications (2)

Publication Number Publication Date
WO2010088000A2 WO2010088000A2 (fr) 2010-08-05
WO2010088000A3 true WO2010088000A3 (fr) 2011-04-07

Family

ID=42396268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000287 Ceased WO2010088000A2 (fr) 2009-02-02 2010-02-02 Composés antifibrotiques et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2010088000A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
CA2857344C (fr) 2011-12-21 2019-02-12 Novira Therapeutics, Inc. Agents antiviraux de l'hepatite b
DK2807160T3 (da) 2012-01-26 2019-10-14 Angion Biomedica Corp Antifibrotiske forbindelser og anvendelser deraf
CN104812743A (zh) 2012-08-28 2015-07-29 爱尔兰詹森科学公司 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途
ES2628953T3 (es) 2013-02-28 2017-08-04 Janssen Sciences Ireland Uc Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
AP2015008968A0 (en) 2013-07-25 2015-12-31 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b
EP3060547B1 (fr) 2013-10-23 2017-10-11 Janssen Sciences Ireland UC Dérivés de carboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
JP2019511542A (ja) 2016-04-15 2019-04-25 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合阻害剤を含む組み合わせ及び方法
CN111867582A (zh) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
CA3132554A1 (fr) 2019-05-06 2020-11-12 Bart Rudolf Romanie Kesteleyn Derives d'amide utiles dans le traitement d'une infection par le virus de l'hepatite b ou de maladies induites par le virus de l'hepatite b

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063330A2 (fr) * 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. Composes de (2-carboxamido) (3-amino) thiophene
US20050154014A1 (en) * 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
US20060074082A1 (en) * 2004-09-17 2006-04-06 Arlindo Castelhano (Arylamidoaryl)cyanoguanidine compounds
WO2006070878A1 (fr) * 2004-12-28 2006-07-06 Astellas Pharma Inc. Derive d'acide carboxylique ou sel de ce derive

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004063330A2 (fr) * 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. Composes de (2-carboxamido) (3-amino) thiophene
US20050154014A1 (en) * 2003-01-06 2005-07-14 Jason Bloxham (2-carboxamido)(3-amino) thiophene compounds
US20060074082A1 (en) * 2004-09-17 2006-04-06 Arlindo Castelhano (Arylamidoaryl)cyanoguanidine compounds
WO2006070878A1 (fr) * 2004-12-28 2006-07-06 Astellas Pharma Inc. Derive d'acide carboxylique ou sel de ce derive

Also Published As

Publication number Publication date
WO2010088000A2 (fr) 2010-08-05

Similar Documents

Publication Publication Date Title
WO2010088000A3 (fr) Composés antifibrotiques et leurs utilisations
WO2011153192A3 (fr) Inhibiteurs des cytochromes p450 et leurs utilisations
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2013112959A8 (fr) Composés antifibrotiques et leurs utilisations
MX2011012122A (es) Derivados de tiofeno.
WO2010084115A3 (fr) Agents antiviraux
WO2012116290A3 (fr) Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant
HK1198869A1 (en) Combination treatments for hepatitis c
WO2009109618A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40
WO2008000483A3 (fr) Composés organiques
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
WO2009109616A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2012168885A3 (fr) Bisacodyle et ses analogues en tant que médicaments pour le traitement du cancer
WO2009109654A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
WO2009041663A1 (fr) Agent destiné à la prévention et/ou au traitement de maladies cutanées
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
WO2011097946A8 (fr) Composés oxazolidinone contenant deux cycles fusionnés, procédé de préparation associé et utilisation associée
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
WO2008074833A3 (fr) Composés
WO2011009714A3 (fr) Dérivés de sel de benzoquinolizinium comme agents anti-cancéreux
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
WO2013019091A3 (fr) Composé d'inhibition de la 11β-hydroxystéroïde déshydrogénase de type 1, et composition pharmaceutique le comprenant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10736165

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10736165

Country of ref document: EP

Kind code of ref document: A2